Century-old Swiss drug giant Roche Group, the parent of Hoffmann-La Roche, is returning to its roots and, potentially, its glory days. Early on, the Basel-based pharmaceutical company made a variety ...

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomideIn a pivotal PPMS study (FENtre ...

Pharmaceutical company Hoffmann-La Roche of Nutley announced that a study published today in The Lancet shows that dialysis patients were effectively switched from frequently dosed anemia drugs to a ...

Opportunities in the biologics market include growth in monoclonal antibodies and parenteral segments, driven by rising chronic diseases and R&D investments. Fastest growth anticipated in Africa and ...

Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...

NEW YORK, Apr 06, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today the appointment of George B. Abercrombie to its Board of Directors. Mr. Abercrombie will serve as a ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

OTTAWA - Health Canada is advising Canadians of its decision to suspend authorization of Avastin for use in the treatment of a certain type of breast cancer (metastatic breast cancer). Based on ...

NEW YORK--(BUSINESS WIRE)--Apr 6, 2010 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today the appointment of George B. Abercrombie to its Board of Directors. Mr. Abercrombie will serve as a ...